Table 3 Model 1: Effects of cognitive impairment (MMSE) measured at baseline on P-ADL level over time estimated by linear mixed model with random effects for intercepts and time ¹

Effect of main variables³

Time

0.27 (0.21; 0.33)

<0.001

0.29 (0.23; 0.34)

<0.001

MMSE at T1

−0.28 (−0.33; −0.23)

<0.001

−0.12 (−0.18; −0.05)

<0.001

MMSE *Time

−0.008 (−0.01; −0.006)

<0.001

−0.009 (−0.01; −0.006)

<0.001

Effect of additional variables at T1⁴

Socio –demographic information

Women

−0.91 (−1.30; −0.52)

<0.001

−0.57 (−0.92; −0.21)

Age (years)

0.11 (0.07; 0.14)

<0.001

0.06 (0.04; 0.10)

<0.001

Single

−0.83 (−1.23; −0.43)

<0.001

−0.31 (−0.68; 0.06)

General somatic health

Very poor

4.32 (3.60; 5.05)

<0.001

3.32 (2.66; 3.97)

<0.001

Poor

2.88 (2.35; 3.41)

<0.001

2.04 (1.56; 2.52)

Fair

1.59 (1.09; 2.10)

<0.001

0.97 (0.52; 1.42)

Good

Reference

Reference

Diagnoses

Dementia

3.98 (3.58; 4.38)

<0.001

1.17 (0.53; 1.80)

MCI

0.98 (0.55; 1.40)

<0.001

−0.10 (−0.53; 0.34)

No

Reference

Reference

Neuropsychiatric sub-syndrome score

Agitation

0.15 (0.11; 0.19)

<0.001

0.04 (−0.008; 0.09)

Psychosis

0.44 (0.35; 0.53)

<0.001

0.18 (0.08; 0.28)

Affective

0.15 (0.12; 0.19)

<0.001

0.03 (−0.01; 0.06)

Use of psychotropic medication

Antipsychotics

1.55 (0.60; 2.50)

0.55 (−0.27; 1.37)

Antidepressants

1.12 (0.63; 1.61)

<0.001

0.51 (0.06; 0.95)

Anxiolytics

1.00 (0.34; 1.65)

0.20 (−0.38; 0.77)

Sedatives

0.49 (0.03; 0.94)

0.17 (−0.23; 0.56)

Cognitive enhancers

1.91 (1.14; 2.67)

<0.001

−0.61 (−1.31; 0.09)